Literature DB >> 27147135

Benign prostatic hyperplasia.

Bilal Chughtai1, James C Forde1, Dominique Dana Marie Thomas1, Leanna Laor1, Tania Hossack2, Henry H Woo2, Alexis E Te1, Steven A Kaplan3.   

Abstract

Benign prostatic hyperplasia (BPH), which causes lower urinary tract symptoms (LUTS), is a common diagnosis among the ageing male population with increasing prevalence. Many risks factors, both modifiable and non-modifiable, can increase the risk of development and progression of BPH and LUTS. The symptoms can be obstructive (resulting in urinary hesitancy, weak stream, straining or prolonged voiding) or irritative (resulting in increased urinary frequency and urgency, nocturia, urge incontinence and reduced voiding volumes), or can affect the patient after micturition (for example, postvoid dribble or incomplete emptying). BPH occurs when both stromal and epithelial cells of the prostate in the transitional zone proliferate by processes that are thought to be influenced by inflammation and sex hormones, causing prostate enlargement. Patients with LUTS undergo several key diagnostic investigations before being diagnosed with BPH. Treatment options for men with BPH start at watchful waiting and progress through medical to surgical interventions. For the majority of patients, the starting point on the treatment pathway will be dictated by their symptoms and degree of bother.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27147135     DOI: 10.1038/nrdp.2016.31

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  66 in total

Review 1.  Safety of Tamsulosin: A Systematic Review of Randomized Trials with a Focus on Women and Children.

Authors:  Steven A Kaplan; Bilal I Chughtai
Journal:  Drug Saf       Date:  2018-09       Impact factor: 5.606

Review 2.  The effect of diet on BPH, LUTS and ED.

Authors:  Mahmoud ElJalby; Dominique Thomas; Dean Elterman; Bilal Chughtai
Journal:  World J Urol       Date:  2018-11-23       Impact factor: 4.226

Review 3.  Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Peng Xiang; Di Guan; Zhen Du; Yongxiu Hao; Wei Yan; Yonghui Wang; Yutong Liu; Dan Liu; Hao Ping
Journal:  Eur Radiol       Date:  2021-01-15       Impact factor: 5.315

4.  Claudin-1 down-regulation in the prostate is associated with aging and increased infiltration of inflammatory cells in BPH.

Authors:  Laura E Pascal; Rajiv Dhir; Goundappa K Balasubramani; Wei Chen; Chandler N Hudson; Pooja Srivastava; Anthony Green; Donald B DeFranco; Naoki Yoshimura; Zhou Wang
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

5.  A NAV2729-sensitive mechanism promotes adrenergic smooth muscle contraction and growth of stromal cells in the human prostate.

Authors:  Qingfeng Yu; Christian Gratzke; Ruixiao Wang; Bingsheng Li; Paul Kuppermann; Annika Herlemann; Alexander Tamalunas; Yiming Wang; Beata Rutz; Anna Ciotkowska; Xiaolong Wang; Frank Strittmatter; Raphaela Waidelich; Christian G Stief; Martin Hennenberg
Journal:  J Biol Chem       Date:  2019-06-26       Impact factor: 5.157

6.  A glimpse at growth hormone-releasing hormone cosmos.

Authors:  Nektarios Barabutis
Journal:  Clin Exp Pharmacol Physiol       Date:  2020-04-25       Impact factor: 2.557

7.  Evaluation of the clinical pharmacist role in improving clinical outcomes in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Mera Ababneh; Duaa Shamieh; Saddam Al Demour; Abeer Rababa'h
Journal:  Int J Clin Pharm       Date:  2019-09-06

Review 8.  Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.

Authors:  Stefan Ückert; George T Kedia; Dimitrios Tsikas; Annika Simon; Andreas Bannowsky; Markus A Kuczyk
Journal:  World J Urol       Date:  2019-09-10       Impact factor: 4.226

9.  Transforming growth factor beta 1 impairs benign prostatic luminal epithelial cell monolayer barrier function.

Authors:  Feng Li; Laura E Pascal; Ke Wang; Yibin Zhou; Goundappa K Balasubramani; Katherine J O'Malley; Rajiv Dhir; Kai He; Donna Stolz; Donald B DeFranco; Naoki Yoshimura; Joel B Nelson; Tie Chong; Peng Guo; Dalin He; Zhou Wang
Journal:  Am J Clin Exp Urol       Date:  2020-02-25

10.  Potential role of glutathione S-transferase P1 gene polymorphism and metabolic syndrome in lower urinary tract symptoms attributed to benign prostatic hyperplasia.

Authors:  Wenjun Zhang; Zheming Li; Miao Liu; Yi Mu; Jun He; Pan Chen; Dongdong Liu; Kehang Chen; Bangwei Che; Shenghan Xu; Hongyan Zhang; Kaifa Tang
Journal:  World J Urol       Date:  2021-07-06       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.